Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18β-glucuronidation: A potential drug interaction

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1011-1014

  Knights, Kathleen M ^a   Kushari, Bowalgaha ^a   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE 18BETA; CANRENOIC ACID; CANRENONE; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; SPIRONOLACTONE; UNCLASSIFIED DRUG; GLUCURONOSYLTRANSFERASE; UGT2B7 PROTEIN, HUMAN;

ARTICLE; CATALYST; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; KIDNEY MICROSOME; LIVER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; IN VITRO STUDY; KIDNEY; LIVER MICROSOME; METABOLISM; MICROSOME;

ALDOSTERONE; BINDING, COMPETITIVE; CANRENOIC ACID; CANRENONE; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; IN VITRO TECHNIQUES; KIDNEY; MICROSOMES; MICROSOMES, LIVER; SPIRONOLACTONE;

EID: 77953783039     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032870     Document Type: Article

References (23)

1. Bledsoe T, Liddle GW, Riondel A, Island DP, Bloomfield D, and Sinclair-Smith B (1966) Comparative fates of intravenously and orally administered aldosterone: evidence for extrahepatic formation of acid-hydrolyzable conjugate in man. J Clin Invest 45:264-269.
2. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503. (Pubitemid 35356875)
3. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
4. Garthwaite SM and McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27-31.
5. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, and Redelmeier DA (2004) Rates of hyperkalemia after publication of the randomized Aldactone Evaluation Study. N Engl J Med 351:543-551. (Pubitemid 39025171)
6. Karim A (1987) Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev 8:151-188.
7. Knights KM, Winner LK, Elliot DJ, Bowalgaha K, and Miners JO (2009) Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 68:402-412.
8. Lewis BC, Mackenzie PI, Elliot DJ, Burchell B, Bhasker CR, and Miners JO (2007) Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol 73:1463-1473.
9. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:189-201.
10. Overdiek HW, Hermens WA, and Merkus FW (1985) New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 38:469-474.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717.
12. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, and Parving HH (2005) Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28:2106-2112.
13. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
14. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
15. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062.
16. Sadée W, Dagcioglu M, and Schröder R (1973) Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 185:686-695.
17. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, and Parving HH (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International 70:536-542.
18. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
19. Tsai R, Davis RP, and Morris DJ (1980) The effect of the antimineralocorticoid, spironolactone on the hepatic synthesis of polar metabolites of aldosterone in male rats. J Steroid Biochem 13:481-487.
20. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
21. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
22. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
23. Vetter H, Appenheimer M, Lucas R, Weiand H, Herschbach ML, Glänzer K, Witassek F, and Krück F (1977) Effect of spironolactone on plasma and urinary aldosterone in primary aldosteronism. Hormone Res 8:23-28. (Pubitemid 8145086)